+4415180811362022: Volume 6, Issue 4
Opinion Article P.1-2
Microdosing Hallucinogenics: Subjective benefits and challenges, substance testing conduct, and the relevance of point.
Author(s): Thomas Anderson*
DOI: 10.35841/aajptr-6.4.116
Mini Review P.1-2
Psilocybin microdosing doesn't influence feeling related side effects and handling: A preregistered field and lab-based study.
Author(s): Michiel Elk*
DOI: 10.35841/aajptr-6.4.117
Perspective P.1-2
Getting through effects of a lone psilocybin segment on resting-state utilitarian organization in sound individuals.
Author(s): Dorota Piechota*
DOI: 10.35841/aajptr-6.4.118
Commentary P.1-2
Connection between metabolic disorder and acylated/desacylated ghrelin proportion in patients with Schizophrenia under olanzapine prescription.
Author(s): Adam Wysokinski*
DOI: 10.35841/aajptr-6.4.119
Rapid Communication P.1-2
Synaptic biomarker decrease and weakened comprehension in the sub-constant PCP mouse model for Schizophrenia.
Author(s): Cameron Carter*
DOI: 10.35841/aajptr-6.4.120